PMC:4134656 / 22418-23168
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4134656","sourcedb":"PMC","sourceid":"4134656","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4134656","text":"Propranolol-resistant IH have also been described as an absence of treatment response either in the proliferative phase or during the post-proliferative phase, after at least 4 weeks of oral propranolol at dosage of ≥2 mg/kg/day.[44] It is reported to occur at a frequency of 0.9% (10/1130). Of the 10 such cases reported from France, 8 had haemangioma on the face. Five children were in the proliferative phase (≤4.2 months) and showed continued growth. The remaining 5 (≥8 months) children, who did not show any decrease in the IH size, were in the post-proliferative phase.[44] This phenomenon needs to be investigated in a large scale studies in order to understand the different factors which influence the treatment outcome in children with IH.","tracks":[{"project":"2_test","denotations":[{"id":"25136206-23659587-58659598","span":{"begin":230,"end":232},"obj":"23659587"},{"id":"25136206-23659587-58659599","span":{"begin":577,"end":579},"obj":"23659587"}],"attributes":[{"subj":"25136206-23659587-58659598","pred":"source","obj":"2_test"},{"subj":"25136206-23659587-58659599","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#93ecae","default":true}]}]}}